Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Study on Internet Medical Models for the Management of Patients With Hypertension in China

30. ledna 2019 aktualizováno: China Cardiovascular Association

A Comparative Study on Internet Medical Models and Conventional Medical Models for the Management of Patients With Hypertension in China

The study is a multi-center, randomized, open, and parallel study. Approximately 958 subjects will be enrolled in 16 sites. The random number table will be adopted to conduct cluster randomization per township hospital/community health service center. Patients will be randomized 1:1 to receive blood pressure management in Internet medical model or Conventional medical model. After follow-ups of 3 months and 6 months, the blood pressure in each group will be observed and compared.

Přehled studie

Postavení

Neznámý

Podmínky

Detailní popis

Protocol Title:A Comparative Study on Internet Medical Models and Conventional Medical Models for the Management of Patients with Hypertension in China Study Indication:Hypertension Number of Site:16sites Study Duration (from the initiation of the first site to the end of the follow-up for the last subject): 12 months Duration of Treatment and Management: 6 months Planned Number of Subjects:958 subjects, 479 in each group(blood pressure management in Internet medical model, Conventional medical model) Internet Medical Model:Using Internet blood pressure management model: home blood pressure self-monitoring + Internet diagnosis + Maintained or adjusted anti-hypertension drug(s) treatment.

Conventional Medical Model:Using Conventional blood pressure management model: home blood pressure monitoring + face-to-face diagnosis in clinic + Maintained or adjusted anti-hypertension drug(s) treatment.

Inclusion Criteria:

  1. Male or female, 45 to 75 years old (including 45and 75 years);
  2. Two measurements of resting systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg on different days during screening;
  3. Female subjects of child-bearing potential who are willing to adopt one of the following methods for contraception during the study:

    • Oral contraceptive, either combined or progestogen alone.
    • Injectable progestogen.
    • Implants of levonorgestrel.
    • Oestrogenic vaginal ring.
    • Percutaneous contraceptive patches.
    • Intrauterine device or intrauterine system showing that the expected failure rate is less than 1% per year as stated in the product label.
    • Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository).
  4. Subjects who can understand and perform home blood pressure monitoring as required by the study;
  5. Subjects who voluntarily participate in the study and sign informed consent form.

Exclusion Criteria:

  1. Two measurements of resting systolic blood pressure ≥ 180mmHg and/or diastolic blood pressure ≥ 110mmHg on different days during screening;
  2. Subjects with the history of cerebral stroke within 6 months prior to screening;
  3. Subjects with the history of myocardial infarction within 6 months prior to screening;
  4. Subjects with the history of heart failure;
  5. Subjects with the history of atrial fibrillation;
  6. Subjects with the history of coronary artery revascularization;
  7. Subjects with other serious diseases, such as tumor;
  8. Subjects diagnosed as the secondary hypertension;
  9. Subjects with congenital or acquired organic heart disease;
  10. Pregnant or lactant subjects;
  11. Subjects with severe mental disease;
  12. Subjects with abnormal liver and renal function: ALT or AST>2 X upper limit value; Or creatinine > 2X upper limit value
  13. Subjects who were previously diagnosed with diabetes that is currently poorly controlled: FBG>10mmol/L;
  14. Subjects who are unable to conduct blood pressure self-test;
  15. The subject has any other known condition at screening that would compromise subject safety, might affect life expectancy, or making it difficult to successfully manage and follow the subject according to the protocol.

Efficacy Evaluations:

Primary Efficacy Endpoints:

  • Blood pressure control rate of subjects in the two groups at Month 6 Secondary Efficacy Endpoints:
  • Blood pressure control rate of subjects in the two groups at Month 3
  • Blood pressure value of subjects in the two groups at Month 3 and Month 6
  • Change of blood pressure of subjects in the two groups at Month 3 and Month 6
  • Variability of blood pressure of subjects in the two groups at Month 3 and Month 6
  • Treatment compliance of subjects in the two groups at Month 3 and Month 6
  • Medical expense of subjects in the two groups at Month 3 and Month 6
  • Treatment satisfaction of subjects in the two groups at Month 3 and Month 6

Typ studie

Intervenční

Zápis (Očekávaný)

958

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

45 let až 75 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  1. Male or female, 45 to 75 years old (including 45 and 75 years);
  2. Two measurements of resting systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg on different days during screening;
  3. Female subjects of child-bearing potential who are willing to adopt one of the following methods for contraception during the study:

    Oral contraceptive, either combined or progestogen alone. Injectable progestogen. Implants of levonorgestrel. Oestrogenic vaginal ring. Percutaneous contraceptive patches. Intrauterine device or intrauterine system showing that the expected failure rate is less than 1% per year as stated in the product label.

    Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository).

  4. Subjects who can understand and perform home blood pressure monitoring as required by the study;
  5. Subjects who voluntarily participate in the study and sign informed consent form.

Exclusion Criteria:

  1. Two measurements of resting systolic blood pressure ≥180mmHg and/or diastolic blood pressure ≥110mmHg on different days during screening;
  2. Subjects with the history of cerebral stroke within 6 months prior to screening;
  3. Subjects with the history of myocardial infarction within 6 months prior to screening;
  4. Subjects with the history of heart failure;
  5. Subjects with the history of atrial fibrillation;
  6. Subjects with the history of coronary artery revascularization;
  7. Subjects with other serious diseases, such as tumor;
  8. Subjects diagnosed as the secondary hypertension;
  9. Subjects with congenital or acquired organic heart disease;
  10. Pregnant or lactant subjects;
  11. Subjects with severe mental disease;
  12. Subjects with abnormal liver and renal function: ALT or AST>2 X upper limit value; Or creatinine >2 X upper limit value;
  13. Subjects who were previously diagnosed with diabetes that is currently poorly controlled: FBG>10mmol/L;
  14. Subjects who are unable to conduct blood pressure self-test;
  15. The subject has any other known condition at screening that would compromise subject safety, might affect life expectancy, or making it difficult to successfully manage and follow the subject according to the protocol.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Jiný
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Jiný: Internet Medical Model
Using Internet blood pressure management model: home blood pressure self-monitoring + Internet diagnosis + Maintained or adjusted anti-hypertension drug(s) treatment.
Subjects in the Internet group should upload blood pressure monitoring data at least once per day. It is highly recommended to upload two pressure monitoring results to capture more blood pressure information. The warning value of blood pressure set in the cloud database is systolic blood pressure ≥ 180mmHg or ≤ 100mmHg and diastolic blood pressure ≥ 110mmHg or ≤ 60mmHg. After enrollment, subjects and physicians communicate via telephone or Internet every two weeks until blood pressure is well controlled judged by physician. Then the frequency of communication will be changed to once a month. Once there are lacks of blood pressure data in 3 days of each week, or. blood pressure values of the subject exceed the warning value in 2 days of consecutive 3 days, the physician will take the initiative to contact the patient for disease inquiry.
Žádný zásah: Conventional Medical Model
Using Conventional blood pressure management model: home blood pressure monitoring + face-to-face diagnosis in clinic + Maintained or adjusted anti-hypertension drug(s) treatment.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Primary endpoint: blood pressure control rate of subjects in the two groups at Month 6
Časové okno: 6 months
Definition of blood pressure control rate is that the percent of subjects with systolic blood pressure <140 mm Hg and diastolic blood pressure < 90 mm Hg
6 months

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Spolupracovníci

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Očekávaný)

1. března 2019

Primární dokončení (Očekávaný)

1. září 2019

Dokončení studie (Očekávaný)

1. prosince 2019

Termíny zápisu do studia

První předloženo

4. května 2018

První předloženo, které splnilo kritéria kontroly kvality

16. května 2018

První zveřejněno (Aktuální)

17. května 2018

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

31. ledna 2019

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

30. ledna 2019

Naposledy ověřeno

1. ledna 2019

Více informací

Termíny související s touto studií

Klíčová slova

Další relevantní podmínky MeSH

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

Ne

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Internet Medical Model

3
Předplatit